Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OMS643762 · 1 trial · 1 indication
Incidence of adverse events
| Arm | Type | Description |
|---|---|---|
| OMS643762 Low Dose | EXPERIMENTAL | Orally administering OMS643762 low dose daily for 14 days |
| OMS643762 High Dose | EXPERIMENTAL | Orally administering OMS643762 high dose daily for 14 days |
| Placebo | PLACEBO_COMPARATOR | Orally administering placebo daily for 14 days |
| OMS643762 Medium Dose | EXPERIMENTAL | Orally administering OMS643762 medium dose daily for 14 days |
| Name | Type | Description |
|---|---|---|
| OMS643762 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Competent to provide informed consent. * Voluntarily provide informed consent and Health Insurance Portability and Accounting Act (HIPAA) Authorization in accordance with local regulations and governing Institutional Review Board (IRB) requirements prior to any procedures or e...
OMS643762 is an investigational small molecule being studied for the treatment of schizophrenia. It is in Phase 2 clinical development and has not been approved by the FDA. The drug is intended for use in patients with this psychiatric condition.
OMS643762 is a small molecule being developed for schizophrenia. Its specific molecular target has not been disclosed in available clinical trial information. The drug is currently in Phase 2 development for this indication.
OMS643762 is being developed by Omeros Corporation, a biopharmaceutical company traded on NASDAQ under the ticker OMER. The company is conducting clinical trials to evaluate the drug's safety and efficacy in schizophrenia.
OMS643762 is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The drug is being studied for the treatment of schizophrenia, with one completed Phase 2 trial.
OMS643762 has one completed clinical trial, NCT01952132, titled "Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects." This Phase 2, randomized, double-blind, placebo-controlled study enrolled 40 participants in the United States.
OMS643762 is the sole name provided for this investigational drug. No alternative names have been reported in the available clinical trial information. It is being developed by Omeros Corporation for schizophrenia.